NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Insulet Corporation PODD
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.7B
▲ 30.7% vs FY2024
EPS · FY25
$3.48
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
18.1%
Net margin · FY25
9.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.7B
Revenue, FY2025 · full 17-year series below
Revenue
Net income
9 cents of every revenue dollar became profit this year.
Per share
USD 3.48
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
18.1%
Return on equity, FY2025
ROE
Operating margin17.5%
Net margin9.1%
Return on assets7.9%
Each USD of equity produced 18 cents of profit this year.
Returned to shareholders
USD 40.6M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 40.6M
Share of profit16.4%
Consecutive raises—
USD 40.6M in buybacks — 16% of the year's profit went back to shareholders.
Growth
+24.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+27.5%
+24.5%
+26.2%
+24.9%
Net income
+277.3%
+105.2%
EPS, diluted
+267.7%
+103.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+6.6%
Change, 10 years+23.6%
The share count grew 7% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.2B
total assets, end of FY2025
Total assetsUSD 3.2B
EquityUSD 1.5B
CashUSD 716.1M
Gross debtUSD 949.2M
Net debtUSD 233.1M
Current ratio2.81×
Net debt stands at 15% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
2.7
2.1
1.7
1.3
1.1
0.9
0.7
0.6
0.5
0.4
0.3
0.2
0.2
0.2
0.2
0.1
0.1
Operating income $B
0.5
0.3
0.2
0.0
0.1
0.1
0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
EBITDA $B
0.6
0.4
0.3
0.1
0.2
0.1
0.1
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.1
Income tax $B
0.1
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
·
·
Net income $B
0.2
0.4
0.2
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
−0.1
−0.1
EPS, diluted $
3.48
5.78
2.94
0.07
0.24
0.10
0.19
0.05
−0.46
−0.48
−1.29
−0.93
−0.83
−1.08
−0.98
−1.54
−2.43
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
18.1
43.0
34.1
0.9
2.9
2.0
8.1
1.8
−24.2
−59.5
−124.7
−49.4
−53.3
−81.7
−61.5
−95.5
−116.9
Shares out B
0.07
0.07
0.07
0.07
0.07
0.07
0.06
0.06
0.06
0.06
0.06
0.06
0.05
0.05
0.05
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
64 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed